Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07568756 · ClinicalTrials.gov registry record · Phase 2

Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation

A Phase 2 study, sponsored by University of California, Irvine.

Not yet
Registry status
Phase 2
Development phase
60
Enrollment target

NCT07568756 is a Phase 2 study that has not yet begun recruiting, run by University of California, Irvine. The registered enrollment target is 60 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07568756, a Phase 2 study, has not yet begun recruiting, sponsored by University of California, Irvine.

NOT YET RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target

Study Summary

This is a phase II single arm, open-label clinical trial determining diagnostic accuracy of Flotufolastat F18 PET in subjects with prostate adenocarcinoma. These are subjects who have not previously received treatment for prostate cancer.

Interventions

  • DIAGNOSTIC_TEST Flotufolastat F18 PET

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2026-05
Est. Completion 2029-05
Phase Phase 2

Sponsor

University of California, Irvine

368 total trials

What the Registry Record Tells You About NCT07568756

The ClinicalTrials.gov registry entry for NCT07568756 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Flotufolastat F18 PET is the first listed.

NCT07568756 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT07568756 about?

NCT07568756 is a clinical study titled "Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation". This is a phase II single arm, open-label clinical trial determining diagnostic accuracy of Flotufolastat F18 PET in subjects with prostate adenocarcinoma. These are subjects who have not previously received treatment for prostate cancer.

What is the current status of trial NCT07568756?

This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2026-05. Estimated completion is 2029-05.

What interventions are being tested in trial NCT07568756?

The interventions under investigation include: Flotufolastat F18 PET (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT07568756?

This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.